SCHEMBL5068853

SCHEMBL5068853

Cc1nc(Nc2ccc(F)cc2)c2nc(C)sc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.47
TRPV1 Q8NER1 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GFER P55789 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
FGFR1 P11362 1/20 0.41
CDK4 P11802 1/20 0.41
CDK2 P24941 1/20 0.41
GAA P10253 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061315 0.88 MAPT (0.44) KDRTRPV1L3MBTL1MAPTALDH1A1
SCHEMBL5064175 0.85 KDR (0.47) KDRTRPV1L3MBTL1MAPTALDH1A1
SCHEMBL5068900 0.85 ADORA3 (0.57) KDRTRPV1MAPTALDH1A1MEN1
SCHEMBL5065463 0.81 MAPT (0.45) KDRTRPV1L3MBTL1MAPTALDH1A1
SCHEMBL5064724 0.81 MEN1 (0.52) TRPV1MAPTMEN1KMT2AFGFR1
SCHEMBL5068960 0.80 TRPV1 (0.40) KDRTRPV1L3MBTL1MAPTALDH1A1
SCHEMBL5068972 0.75 TRPV1 (0.53) TRPV1MAPTKMT2ASMN1; SMN2
SCHEMBL5064108 0.75 TRPV1 (0.41) KDRTRPV1MAPTRAB9AADORA3
SCHEMBL3937929 0.72 ALDH1A1 (0.40) KDRTRPV1L3MBTL1MAPTALDH1A1
SCHEMBL16604696 0.72 ADORA3 (0.35) ADORA3ADORA2AADORA2BADORA1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US claimed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP claimed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 KDR 202/4885TRPV1 1569/4885L3MBTL1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.